Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases

THOUSAND OAKS, Calif., Jan. 4, 2023 /PRNewswire/ -- Capsida Biotherapeutics Inc. ("Capsida") today announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned subsidiary of Eli Lilly and Company ("Lilly"), to develop transformative genetic...

Click to view original post